Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612560 · ClinicalTrials.gov registry record · NA
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00612560 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 28 participants.
The verdict
NCT00612560, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the effect of combined flaxseed and aromatase inhibitor therapy on breast cancer treatment. Because of the increasing use of both complementary and alternative approaches to treatment, and the use of aromatase inhibitors in the treatment of breast cancer, the proposed study has potential to provide important clinical information about the effect of foods high in phytoestrogens on a common endocrine therapy used in breast cancer.
Interventions
- DRUG Placebo
- DRUG Anastrozole
- DIETARY_SUPPLEMENT flaxseed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612560
The ClinicalTrials.gov registry entry for NCT00612560 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00612560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612560 about?
NCT00612560 is a clinical study titled "Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics". The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the effect of combined flaxseed and aromatase inhibitor therapy on breast c...
What is the current status of trial NCT00612560?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2007-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00612560?
The interventions under investigation include: Placebo (DRUG), Anastrozole (DRUG), flaxseed (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00612560?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.